IMRX Earnings & Financial Statements
Immuneering Corporation
$3.64
+$0.22(+6.43%)
28
Overall
40
Value
18
Tech
28
Quality
Market Cap
$221.27M
Volume
934.08K
52W Range
$3.60 - $8.48
Target Price
$17.50
IMRX earnings and financial statements: Immuneering Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
IMRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | $19.2K | $147.9K | $317.0K | $2.08M |
| Cost of revenue | - | - | - | $158.1K | $1.15M |
| Operating income | -$59.38M | -$64.07M | -$58.41M | -$51.74M | -$33.89M |
| EBITDA | -$56.81M | -$60.32M | -$52.01M | -$51.47M | -$33.68M |
| Net income | -$56.02M | -$61.04M | -$53.47M | -$50.51M | -$33.54M |
| EPS (diluted) | $-1.27 | $-2.04 | $-1.88 | $-1.90 | $-2.46 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $231.99M | $52.71M | $102.58M | $122.37M | $166.70M |
| Total liabilities | $13.50M | $11.33M | $12.01M | $12.52M | $10.72M |
| Shareholders’ equity | $218.48M | $41.39M | $90.58M | $109.85M | $155.98M |
| Cash and equivalents | $128.65M | $36.14M | $59.41M | $72.64M | $74.89M |
| Long-term debt | $3.43M | $3.82M | $4.16M | $4.46M | $5.09M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$45.34M | -$55.00M | -$48.97M | -$44.10M | -$30.85M |
| Capital expenditure | -$142.2K | -$84.9K | -$342.7K | -$742.5K | -$60.8K |
| Free cash flow | -$45.49M | -$55.08M | -$49.31M | -$44.84M | -$30.91M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IMRX | $3.64 | +6.4% | 934.08K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |